Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review

P.J. Devereaux, Lee Goldman, Salim Yusuf, Ken Gilbert, Kate Leslie, Gordon H. Guyatt

Abstract

This is the second of 2 articles evaluating cardiac events in patients undergoing noncardiac surgery. Unrecognized myocardial infarctions (MIs) are common, and up to 50% of perioperative MIs may go unrecognized if physicians rely only on clinical signs or symptoms. In this article, we summarize the evidence regarding monitoring strategies for perioperative MI in patients undergoing noncardiac surgery. Perioperative troponin measurements and 12-lead electrocardiograms can detect clinically silent MIs and provide independent prognostic information. Currently, there are no standard diagnostic criteria for perioperative MIs in patients undergoing noncardiac surgery. We propose diagnostic criteria that reflect the unique features of perioperative MIs. Finally, we review the evidence for perioperative prophylactic cardiac interventions. There is encouraging evidence that some perioperative interventions (e.g., β-blockers, α2-adrenergic agonists, statins) may prevent major cardiac ischemic events, but firm conclusions await the results of large definitive trials. The best evidence does not support a management strategy of preoperative coronary revascularization before noncardiac surgery.

CMAJ 2005;173(7):779-88

Unrecognized MIs are not restricted to the perioperative setting. Eight large cohort studies (samples over 1000), which were not confined to patients undergoing surgery (e.g., the Framingham Study), evaluated the frequency of unrecognized MIs among more than 65 000 people based on the new appearance of diagnostic Q waves (typically ≥ 30 ms in 2 or more anatomically adjacent leads). In these studies, 3237 MIs occurred, of which 945 (29%; 95% confidence interval [CI] 28%–31%) were not detected at the time of the event. These MIs were not benign: patients experiencing an unrecognized MI have a prognosis similar to that of patients experiencing a recognized MI.

To estimate the frequency of perioperative clinically unrecognized MI, we evaluated all prospective cohort studies of patients undergoing noncardiac surgery that fulfilled the following criteria: sample greater than 300 patients, surgery not restricted to a specific type (e.g., vascular surgery), at least 1 measurement of a cardiac enzyme or biomarker after surgery, and an accounting of the patients experiencing a perioperative MI who had no clinical signs or symptoms suggestive of an MI (Table 1). The pooled results from the 3 eligible studies suggest that only 14% (95% CI 3%–25%) of patients experiencing a perioperative MI will have chest pain and only 53% (95% CI 38%–68%) will have a clinical sign or symptom that may trigger a physician to consider an MI.

Although the number of events is small, the large proportion of clinically unrecognized MIs is plausible. First, the majority of perioperative MIs occur during the first 3 days after surgery, a period when most patients receive analgesics (e.g., narcotics), which can blunt cardiac pain perception. Second, a small but high-risk group of surgical patients will require intubation and sedation during the...
highest risk period, which limits their ability to communicate symptoms. Third, surgical patients experiencing potential signs (e.g., hypotension, tachycardia) or symptoms (e.g., shortness of breath, nausea) of MI have a host of more common potential explanations (e.g., atelectasis, pneumonia, hypovolemia, bleeding, medication side effect), and physicians may therefore not consider MI.

Diagnosing perioperative MIs in patients undergoing noncardiac surgery

Currently, there are no standard diagnostic criteria for perioperative MI in patients undergoing noncardiac surgery. Optimal diagnostic criteria must consider the unique features of perioperative MIs, in particular that a large proportion are clinically silent. We propose diagnostic criteria for perioperative MIs (Box 1) that we have adapted from a recent consensus document of the joint European Society of Cardiology / American College of Cardiology (ESC/ACC) committee that redefined nonperioperative MI16 (Box 2).

The first of our criteria requires a typical rise in troponin or a typical fall of an elevated troponin level detected at its peak after surgery in a patient without a documented alternative explanation for an elevated troponin level (e.g., pulmonary embolism) or — only if troponin measurement is unavailable — a rapid rise and fall of CK-MB. We encourage physicians to use troponin measurement, because perioperative CK-MB measurements are prone to false-positive and false-negative values. Surgical trauma can result in the release of CK-MB from skeletal muscle and a false-positive CK-MB value for MI.17-19 A substantial proportion of perioperative MIs occur in the first 2 days after surgery, when serum CK values are high secondary to surgical trauma. These high CK values can result in a low, and thus false-negative, ratio of CK-MB to total CK.19,20 Given the limitations of CK-MB measurement in the perioperative setting, physicians should only use CK-MB if troponin measurement is unavailable at their centre.

As troponin values rise, their variability, as measured by the coefficient of variation, decreases. The ESC/ACC guidelines define an increased troponin level as “a measurement exceeding the 99th percentile of a reference control group.” At the same time, however, they specify that the coefficient of variation at the 99th percentile should be 10% or less. Unfortunately, no available troponin assay meets the 10% coefficient of variation criterion at the 99th percentile — higher levels (above the 99th percentile) are required to meet this criterion.21,22 In keeping with previous suggestions,21,23 until the assays are improved to meet the ESC/ACC recommendation, we define an increased troponin level as the lowest value that has a coefficient of variation equal to 10% (Appendix 1).

New Q-wave changes (≥30 ms) present in any 2 contiguous leads fulfill the definition of the development of

Table 1: Incidence of myocardial infarction (MI) and presence of signs or symptoms among patients undergoing noncardiac surgery

| Study          | No. of patients | Incidence of MI; no. (%) of patients | Study definition of MI                                                                 |
|----------------|-----------------|--------------------------------------|---------------------------------------------------------------------------------------|
|                | No. of patients | Total | With chest pain | With any sign or symptom | Elevated CK-MB value and 1 of the following: |
| Mangano et al¹ | 474             | 12 (3) | 1 (8)           | 8 (67) | • new Q-wave changes |
| Ashton et al²  | 512             | 8 (2)  | 2 (25)          | 5 (62) | • persistent ST-segment and T-wave changes |
| Badner et al³  | 323             | 18 (6) | 3 (17)          | 7 (39) | • autopsy evidence |
| Total (pooled result) | 1309           | 38 (3) | 6 (14)          | 20 (53) | 2 of the following: |
|                |                 |        |                 |        | • new Q-wave changes |
|                |                 |        |                 |        | • elevated CK-MB value |
|                |                 |        |                 |        | • positive pyrophosphate scan |
|                |                 |        |                 |        | Elevated CK level and 2 of the following: |
|                |                 |        |                 |        | • elevated CK-MB/CK ratio |
|                |                 |        |                 |        | • new Q-wave changes |
|                |                 |        |                 |        | • elevated troponin level |
|                |                 |        |                 |        | • positive pyrophosphate scan |

Note: CK-MB = creatine kinase MB isoenzyme.
*The results were pooled with the use of a fixed-effects model. The pooled results did not show significant heterogeneity (MI with chest pain, p = 0.57 for heterogeneity; MI with any sign or symptom, p = 0.24 for heterogeneity).
pathological Q waves. We define electrocardiogram (ECG) changes indicative of ischemia as ST-segment elevation (≥ 2 mm in leads V1, V2 or V3) or ≥ 1 mm in the other leads) or ST-segment depression (≥ 1 mm) in at least 2 contiguous leads, or symmetric inversion of T waves (≥ 1 mm) in at least 2 contiguous leads. Coronary artery intervention includes percutaneous coronary intervention or coronary artery bypass grafting (CABG).

Because many patients will not experience symptoms, clinicians may still miss the correct diagnosis in patients with an elevated troponin level after surgery who have experienced an MI. Some of these patients will have an uninterpretable ECG (e.g., paced, left bundle-branch block, chronic ST-segment changes); some will have an infarct in a territory (e.g., posterior) where the conventional ECG lacks sensitivity;24 and some will have significant ST-segment changes that resolve by the time the ECG is repeated the following day. To avoid missing the diagnosis of MI, we have added to the first criterion the finding of a new or presumed new wall-motion abnormality on echocardiography or a new or presumed new fixed cardiac defect on radionuclide imaging.

When physicians encounter a patient who has an elevated troponin level after surgery without either ischemic symptoms or a diagnostic ECG, the differential diagnosis includes MI and noncardiac causes (e.g., pulmonary embolism). Because MI is a probable cause of an elevated troponin level in this situation, physicians should consider obtaining an echocardiogram or radionuclide imaging.

Although physiologic studies suggest that an imaging study may be insensitive (an injury involving > 20% of myocardial wall thickness may be required to detect a wall-motion abnormality on echocardiography, and an injury of myocardial tissue > 10 g may be required to detect a radionuclide perfusion defect),16 at least 1 clinical study has suggested that echocardiography has a high sensitivity: 108 patients had troponin levels measured before surgery and every 6 hours for the first 36 hours after surgery, as well as echocardiography before surgery and 3–5 days after surgery.19 Echocardiography demonstrated a new wall-motion abnormality in all but 1 of the 9 patients who experienced an MI based on the diagnostic criteria of an elevated troponin level and significant ECG changes. This study also suggested excellent specificity for echocardiography. None of the remaining 99 patients had a new wall-motion abnormality. These results suggest that a wall-motion abnormality detected on an imaging study in the absence of a prior study suggests the diagnosis of perioperative MI, and a demonstrably new abnormality increases the likelihood further and thus supports our definition of a perioperative MI.

Further research is needed to evaluate the diagnostic criteria we propose.

**Prognostic factors**

**Cardiac biomarkers**

Perioperative measurement of cardiac enzymes or biomarkers not only can help to identify otherwise silent MI but may also contribute important prognostic information.

---

**Box 1: Proposed diagnostic criteria for perioperative myocardial infarction in patients undergoing noncardiac surgery**

The diagnosis of perioperative MI requires any 1 of the following criterion:

- **Criterion 1:** A typical rise in the troponin level or a typical fall of an elevated troponin level detected at its peak after surgery in a patient without a documented alternative explanation for an elevated troponin level (e.g., pulmonary embolism); or a rapid rise and fall of CK-MB only if troponin measurement is unavailable.* This criterion requires that 1 of the following criteria must also exist:
  - Ischemic signs or symptoms (e.g., chest, arm or jaw discomfort, shortness of breath, pulmonary edema)
  - Development of pathological Q waves on an ECG
  - ECG changes indicative of ischemia
  - Coronary artery intervention
  - New or presumed new cardiac wall-motion abnormality on echocardiography, or new or presumed new fixed defect on radionuclide imaging
- **Criterion 2:** Pathological findings of an acute or healing MI
- **Criterion 3:** Development of new pathological Q waves on an ECG if troponin levels were not obtained or were obtained at times that could have missed the clinical event

Note: CK-MB = creatine kinase MB isoenzyme, ECG = electrocardiogram

*B Because CK-MB is both less sensitive and less specific in the perioperative setting compared with other settings and compared with troponin levels, it should be used for diagnostic purposes only when troponin levels are not obtainable.

**Box 2: Diagnostic criteria for nonperioperative myocardial infarction of the European Society of Cardiology / American College of Cardiology**

A. The diagnosis of acute, evolving or recent MI requires either of the following criteria:

- **Criterion 1:** A typical rise and gradual fall (troponin) or a more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least 1 of the following:
  - Ischemic symptoms
  - Development of pathological Q waves on an ECG
  - ECG changes indicative of ischemia
  - Coronary artery intervention
- **Criterion 2:** Pathological findings of an acute MI

B. The diagnosis of established MI requires either of the following criteria:

- **Criterion 1:** Development of new pathological Q waves on serial ECGs
- **Criterion 2:** Pathological findings of a healed or healing MI

Note: CK-MB = creatine kinase MB isoenzyme, ECG = electrocardiogram.
To assess the prognostic value of perioperative troponin and CK-MB measurements, we evaluated all noncardiac surgery studies that fulfilled the following criteria: at least 1 troponin or CK-MB measurement after surgery; reporting short-term (<30 days after surgery) cardiac or total mortality, or intermediate (≤1 year after surgery) or long-term (>1 year after surgery) mortality or major cardiac events; and assessment of the prognostic value of perioperative troponin and CK-MB measurements through multivariable analysis.

The 6 eligible studies, which included a total of 2175 patients and 249 events (Table 2), evaluated CK-MB, troponin T, troponin I or both troponin T and I. In all 6 studies, troponin measurement proved to be a statistically significant independent predictor of intermediate and long-term outcomes (i.e., mortality and major cardiac events). This finding persisted even in the 2 studies that excluded patients who experienced a perioperative MI. Two studies evaluated and demonstrated a dose–response relation — the higher the peak troponin value, the higher the 1-year mortality. In contrast, 3 of the 4 studies that assessed CK-MB failed to show an association between an elevated CK-MB value and intermediate or long-term outcomes. The authors of one of the studies published a second paper evaluating the same patients but excluding deaths in the first month after surgery and extending the follow-up period from 1 to 2 years. In this second paper, an elevated perioperative troponin value did not significantly predict the few deaths between months 1 to 24 after surgery (odds ratio 2.7, 95% CI 0.7–10), which suggests that an elevated perioperative troponin value more strongly predicts mortality in the first 12 months after surgery.

We did not evaluate the short-term predictive power of troponin or CK-MB values for diagnosing MI because they are now part of the diagnostic criteria. Troponin was not, however, part of the diagnostic criteria when one of the earlier studies showed its prognostic benefit.

Electrocardiography

We evaluated studies using the same eligibility criteria for troponin and CK-MB measurement, made specific for electrocardiography, to assess the prognostic value of ECG evidence of perioperative ischemia. Because of the consistency with which an elevated perioperative troponin value proved to be an independent predictor of major outcomes after surgery, we also required that studies include troponin in their multivariable analysis. Three studies met our criteria (Table 3).

Filipovic and colleagues did not demonstrate a statistically significant association between 3-lead ECG evidence of perioperative ischemia and mortality after surgery, probably because ECG monitoring with fewer leads has lower sensitivity than monitoring with 12 leads. The other 2 studies, one of which excluded patients who experienced an MI within 30 days after surgery, demonstrated a statistically significant association, independent of perioperative troponin values, between perioperative ischemia on a 12-lead ECG and long-term mortality.

Table 2: Prognostic value of perioperative troponin and CK-MB measurements in patients undergoing noncardiac surgery

| Study                  | No. of patients | Variables adjusted for in analysis                                                                 | Primary outcome                          | Association of elevated troponin level to outcome* | Association of elevated CK-MB level to outcome* |
|------------------------|-----------------|-----------------------------------------------------------------------------------------------------|------------------------------------------|--------------------------------------------------|-------------------------------------------------|
| Kim et al              | 229             | Age, CHF, TAA surgery, perioperative β-blocker therapy                                               | Total mortality at 6 mo (n = 18)         | OR 5.9 (1.6–22)                                  | NA                                              |
| Landesberg et al       | 447             | Age, MI, renal failure, type of vascular surgery                                                     | Total mortality at 32 mo (n = 82)        | OR 2.15 (1.4–3.4)                                | OR 2.71 (1.5–5)                                 |
| Filipovic et al        | 173             | Age, renal failure, CHF, hypertension, diabetes, anesthetic used, heart rate variability, ECG evidence of ischemia, elevated CK-MB value | Mortality at 12 mo (n = 28)              | OR 10.2 (2.8–37)                                 | OR 6.9 (0.8–56)                                 |
| Oscarsson et al        | 161             | BMI, ASA score, perioperative β-blocker and diuretic therapy, perioperative tachycardia              | Mortality at 12 mo (n = 22)              | HR 15 (4–60)                                    | NA                                              |

Studies that excluded patients who had an MI before hospital discharge or within 30 days after surgery

| Study                  | No. of patients | Variables adjusted for in analysis                                                                 | Primary outcome                          | Association of elevated troponin level to outcome* | Association of elevated CK-MB level to outcome* |
|------------------------|-----------------|-----------------------------------------------------------------------------------------------------|------------------------------------------|--------------------------------------------------|-------------------------------------------------|
| Lopez-Jimenez et al    | 772             | Age, sex, history of cardiac disease, diabetes, smoking, type of surgery, CK-MB level               | Composite outcome at 6 mo (n = 19)       | OR 4.6 (p < 0.05)                                 | RR 1.2 (0.5–3.2)                                |
| Kertai et al           | 393             | Clinical risk score, ECG evidence of ischemia                                                       | Mortality at 48 mo (n = 80)              | HR 1.9 (1.1–3.1)                                 | HR 1.6 (0.7–3.4)                                |

Note: ASA = American Society of Anesthesiologists, BMI = body mass index, CHF = congestive heart failure, CK-MB = creatine kinase MB isoenzyme, ECG = electrocardiogram, HR = hazard ratio, MI = myocardial infarction, NA = not assessed, OR = odds ratio, RR = relative risk, TAA = thoracoabdominal aneurysm.

*Numbers in parentheses are 95% confidence intervals, unless stated otherwise.
The ECG, like biomarkers, is part of the diagnostic criteria for MI, but it also is often the sole criterion for myocardial ischemia in the absence of infarction. Even a single postoperative ECG demonstrating ischemia in the recovery room is predictive of a major cardiac complication later during the hospital stay.\

### Use of diagnostic and prognostic data

If clinicians wish to avoid missing a significant proportion of perioperative MIs and identify patients at high risk of intermediate or long-term major cardiac events, they should consider monitoring troponin levels and ECGs daily during the first 3 days after surgery. Choosing whom to monitor presents a challenge. The risk of missing an asymptomatic infarct increases with increasing postoperative risk of major cardiac events. A reasonable threshold would be to obtain troponin levels and ECGs for patients with established atherosclerotic disease (i.e., coronary artery disease and peripheral vascular disease) who are undergoing surgery requiring hospital admission. An alternative threshold would be to monitor patients who have other risk factors for perioperative cardiac events (e.g., diabetes mellitus, renal insufficiency, or a history of heart failure or cerebrovascular disease). Definitive recommendations await the results of further studies.

### Interventions to prevent perioperative cardiac events

The multiple triggers and states (i.e., inflammatory, hypercoagulable, hypoxic and stress states) that may result in an MI in patients undergoing noncardiac surgery, which we discussed in the first article in this series,1 open the possibility for a variety of potential prophylactic interventions. We will review the evidence for perioperative prophylactic use of β-blockers, calcium-channel blockers, α₂-adrenergic agonists, coronary revascularization, 3-hydroxy-3-methylglutaryl (HMG)–coenzyme A reductase inhibitors (i.e., statins) and acetylsalicylic acid (ASA) in patients undergoing noncardiac surgery (Table 4).31–46

In considering the evidence for these interventions, readers should keep in mind 2 points. First, it is only realistic to expect moderate treatment effects (i.e., relative risk reductions of 20%–35%). Even when an intervention effectively blocks one or more pathogenic mechanisms, there will remain a number of unaffected pathogenic mechanisms; thus, large treatment effects are unlikely. Second, even assuming a high rate of perioperative cardiovascular events of 10%, trials need at least 350, and ideally 650, events to convincingly demonstrate a 25% relative risk reduction.47

### β-Blockers

β-Blockers moderate the effects of increased catecholamine levels and therefore may prevent perioperative cardiac events.48,49 Many authors and 2 guideline committees have recommended that patients with coronary artery disease or risk factors for coronary artery disease undergoing noncardiac surgery receive perioperative β-blocker therapy.50–55 Important developments have occurred since these recommendations, and subsequent reviews,56,57 were published.

Proponents of β-blocker prophylaxis have based their recommendations primarily on the results of 2 randomized controlled trials (RCTs) (Table 4).35,37 These 2 trials have limitations. Poldermans and colleagues35 stopped their unblinded trial after an interim analysis based on 20 outcomes, and they demonstrated an implausible relative risk reduction of 90% in the composite outcome of cardiac death and nonfatal MI. In a second trial, by Mangano and colleagues,51 the results were no longer statistically significant when patients who died while receiving the study drug were included in the intention-to-treat analysis.52

In contrast, the results from 2 recent trials did not demonstrate any benefit from β-blocker therapy.16,18 Although these 2 trials had a greater number of cardiac events and enrolled more patients than the 2 previous trials, they were nonetheless underpowered to determine the impact of β-blocker therapy on major cardiovascular outcomes. However, their findings indicate that the results from the earlier trials were overly optimistic. Ongoing trials19 will help to resolve the inconsistency in the results of the current perioperative β-blocker trials.

### Calcium-channel blockers and α₂-adrenergic agonists

Calcium-channel blockers dilate coronary arteries;57 α₂-adrenergic agonists suppress the release of catecholamines.42,58 These effects may prevent perioperative cardiac events. In Table 4 we present the results from 2 recent sys-

| Table 3: Prognostic value of ECG evidence of perioperative ischemia in patients undergoing noncardiac surgery |
|---------------------------------------------------------------|-----------------|--------------------------------------------------|
| Study | ECG monitoring method | Association of ECG evidence with death after surgery* |
|-------|-------------------|-----------------------------------------------|
| Landesberg et al52 | Continuous 12-lead ECG monitoring for 48–72 h after surgery | OR 2.20 (p = 0.03) |
| Filipovic et al50 | Continuous 3-lead ECG monitoring for 48 h after surgery | OR 2.0 (0.3–12) |
| Kertai et al50 | 12-lead ECG on postoperative days 2, 3 and 7 | HR 1.8 (1.0–3.1) |

Note: ECG = electrocardiogram, OR = odds ratio, HR = hazard ratio. *
Numbers in parentheses are 95% confidence intervals, unless stated otherwise.
### Table 4: Results of studies evaluating the effectiveness of perioperative prophylactic cardiac interventions

| Intervention study | Study design | Outcome | Group; no. of events / no. of patients | RR* (95% CI) | Comments |
|--------------------|--------------|---------|----------------------------------------|--------------|----------|
| **β-blocker therapy** |              |         |                                        |              |          |
| Short-term follow-up (30 d after surgery) |             |         |                                        |              |          |
| Poldermans et al[35] | RCT          | Cardiac death or nonfatal MI | 2/59 | 18/53 | 0.10 (0.02–0.41) | Unblinded trial; stopped early after first interim analysis |
| Yang et al[36] | RCT          | Cardiac death or nonfatal MI | 19/246 | 22/250 | 0.88 (0.49–1.58) | Blinded trial; not stopped after interim analysis |
| **Long-term follow-up** |              |         |                                        |              |          |
| Mangano et al[37] | RCT          | Total mortality at 2 yr | 13/99 | 23/101 | 0.58 (0.31–1.07) | Authors reported statistically significant result but excluded patients who died while taking study drug. Result was not significant after we included all deaths in intention-to-treat analysis |
| Juul et al[38] | RCT          | Total mortality, MI, UA or CHF at 18 mo | 99/462 | 93/459 | 1.06 (0.82–1.36) | Authors included all events. Total mortality was the same in both groups (16%) |
| **Calcium-channel blocker therapy** |              |         |                                        |              |          |
| Short-term follow-up |             |         |                                        |              |          |
| Wijeysundera et al[39] | MA of RCTs  | Total mortality | 5/358 | 12/334 | 0.40 (0.14–1.16) | MA included 11 RCTs, of which 8 evaluated diltiazem, 2 evaluated verapamil and 2 evaluated dihydropyridines |
| **α₂-Adrenergic agonist therapy** |              |         |                                        |              |          |
| Short-term follow-up |             |         |                                        |              |          |
| Wijeysundera et al[40] | MA of RCTs  | Total mortality (vascular surgery) | 13/877 | 26/771 | 0.47 (0.25–0.90) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| Oliver et al[41] | RCT          | Total mortality (nonvascular, noncardiac surgery) | 45/859 | 65/757 | 0.66 (0.46–0.94) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| |                   | MI (nonvascular, noncardiac surgery) | 16/512 | 15/501 | 1.09 (0.52–2.09) | |
| |                   | MI (nonvascular, noncardiac surgery) | 36/502 | 26/491 | 1.35 (0.83–2.21) | |
| |                   | MI (vascular surgery) | 26/771 | 52/491 | 1.35 (0.83–2.21) | |
| Oliver et al[41] | RCT          | MI (vascular surgery) | 45/859 | 65/757 | 0.66 (0.46–0.94) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| |                   | MI (nonvascular, noncardiac surgery) | 16/512 | 15/501 | 1.09 (0.52–2.09) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| |                   | MI (nonvascular, noncardiac surgery) | 36/502 | 26/491 | 1.35 (0.83–2.21) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| |                   | MI (vascular surgery) | 26/771 | 52/491 | 1.35 (0.83–2.21) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| |                   | MI (nonvascular, noncardiac surgery) | 16/512 | 15/501 | 1.09 (0.52–2.09) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| |                   | MI (vascular surgery) | 26/771 | 52/491 | 1.35 (0.83–2.21) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| |                   | MI (nonvascular, noncardiac surgery) | 16/512 | 15/501 | 1.09 (0.52–2.09) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| Oliver et al[41] | RCT          | MI (vascular surgery) | 45/859 | 65/757 | 0.66 (0.46–0.94) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| |                   | MI (nonvascular, noncardiac surgery) | 16/512 | 15/501 | 1.09 (0.52–2.09) | Results were reported separately for patients who underwent vascular surgery and those who underwent nonvascular, noncardiac surgery. MA included 12 RCTs of noncardiac surgery, of which 8 included vascular surgery |
| Wallace et al[42] | RCT          | Total mortality | 91/946 | 100/941 | 0.89 (0.67–1.18) | This trial was included in the MA by Wijeysundera et al[40]. We included it here because it accounts for 56 of the 70 deaths and 157 of the 172 MIs in the MA |
| |                   | Total mortality or nonfatal MI | 22/946 | 34/941 | 0.61 (0.35–1.03) | |
| **Preoperative coronary artery revascularization** |              |         |                                        |              |          |
| Long-term follow-up (2 yr) |             |         |                                        |              |          |
| McFalls et al[43] | RCT          | Total mortality | 70/258 | 67/252 | 0.98 (0.70–1.37) | Of the patients assigned to coronary artery revascularization, 38% underwent CABG, 55% underwent PCI, and 7% did not receive coronary revascularization |
| **Statin therapy** |              |         |                                        |              |          |
| 6-mo follow-up after surgery |             |         |                                        |              |          |
| Durazzo et al[44] | RCT          | Cardiac death, nonfatal MI, ischemic stroke or UA | 4/50 | 13/50 | 0.31 (0.11–0.88) | None of the individual outcomes demonstrated statistically significant results |
| **Antiplatelet therapy** |              |         |                                        |              |          |
| Short-term follow-up |             |         |                                        |              |          |
| Robless et al[45] | MA of RCTs  | Vascular death, nonfatal MI, or nonfatal stroke | 76/893 | 92/872 | OR 0.76 (0.54–1.05) | Patients underwent infra-inguinal bypass surgery. MA included 10 RCTs, 6 of which evaluated effects of ASA |
| Robless et al[45] | RCT          | Death from ischemic heart disease or nonfatal MI | 105/6679 | 79/6677 | HR 1.33 (1.00–1.78) | ASA therapy was evaluated in patients undergoing surgical repair of hip fracture |

Note: ASA = acetylsalicylic acid, CABG = coronary artery bypass grafting, CHF = congestive heart failure, CI = confidence interval, MA = meta-analysis, MI = myocardial infarction, PCI = percutaneous coronary intervention, PEP trial = Pulmonary Embolism Prevention trial, RCT = randomized controlled trial, UA = unstable angina.

*Relative risks are reported, unless stated otherwise.
tematic reviews and meta-analyses that evaluated the effects of perioperative calcium-channel blockers and α₂-adrenergic agonists in patients undergoing noncardiac surgery. The results of the meta-analysis of calcium-channel blockers were not statistically significant; however, there were too few events from which to draw conclusions. More research is needed to determine the effect of perioperative calcium-channel blocker therapy.

A meta-analysis of α₂-adrenergic agonists demonstrated a statistically significant reduction in both mortality and incidence of MI with α₂-adrenergic agonist therapy among the patients who underwent vascular surgery. The investigators, however, found no effect on mortality and MI incidence among the patients who underwent nonvascular, noncardiac surgery.

Although there were 12 RCTs included in the meta-analysis of α₂-adrenergic agonists, a single study accounted for most of the events. In this trial, 2854 patients were included in the randomization, but the published report excluded 957 of them at high risk of coronary artery disease because an interim analysis showed that they had a lower than expected event rate. The investigators then focused on the remaining 1897 patients with established coronary artery disease, 52% of whom underwent thoracic, abdominal or orthopedic surgery. Mivazerol therapy resulted in a statistically significant reduction in the composite outcome of total mortality and nonfatal MI only in the subgroup of patients who underwent vascular surgery.

An RCT completed since the publication of the meta-analysis of α₂-adrenergic agonists evaluated the long-term effects of perioperative clonidine in patients undergoing noncardiac surgery. Clonidine was found to have no effect on the incidence of MIs (4 events) during the original hospital admission, but the trial results suggested a mortality benefit at 2 years after surgery.

Although the results of the meta-analysis of α₂-adrenergic agonists are encouraging, they warrant a cautious interpretation. The most recent clonidine trial is also encouraging, but given there were few events, unrealistic relative risk reductions and results of borderline statistical significance, the results may represent a chance finding. Confirmation of these results is required in a large, well-designed trial.

**Coronary revascularization**

The use of coronary revascularization before noncardiac surgery is based on the assumption that perioperative MIs occur primarily in coronary arteries with hemodynamically significant stenoses and that revascularization may therefore prevent infarction. As we discussed in the first article in this series, this assumption may be erroneous.

Although some observational studies suggested a benefit of coronary revascularization before noncardiac surgery, a recent RCT has revealed that coronary revascularization performed in patients with chronic stable angina had no effect on outcomes after elective vascular surgery for abdominal aortic aneurysm or severe leg claudication (Table 4).

This trial excluded patients with unstable angina, some of whom may benefit from coronary revascularization before noncardiac surgery. Small observational studies suggest that patients should have their noncardiac surgery delayed for at least 1 month following CABG and 6 weeks following angioplasty with a bare-metal stent. The optimal period to delay noncardiac surgery following use of a cardiac drug-eluting stent is unknown. However, it is probably substantially longer than 6 weeks, because drug-eluting stents delay endothelialization compared with bare-metal stents, and their use likely prolongs the period of risk for late stent-related thrombosis.

**Statins**

Statins have plaque-stabilizing properties and therefore may prevent perioperative cardiac events. Three observational studies suggest that statin therapy reduces the risk of perioperative death in patients undergoing noncardiac surgery. The 1 RCT that evaluated the effects of perioperative statin therapy in patients undergoing vascular surgery demonstrated a statistically significant benefit, but there were few events (Table 4).

Given the limited current evidence (i.e., 17 events in the only RCT, implausibly large relative risk reduction, borderline statistically significant result for a broad composite outcome), the effectiveness of perioperative statin therapy remains uncertain. The evidence does, however, provide the impetus for an adequately powered RCT to determine whether perioperative statin therapy prevents major perioperative cardiac events.

**Acetylsalicylic acid**

ASA suppresses platelet aggregation and therefore may prevent perioperative cardiac events. A systematic review of antiplatelet therapy versus placebo in patients undergoing infrainguinal bypass surgery offers encouraging evidence that antiplatelet therapy prevents vascular events (Table 4). In contrast, the Pulmonary Embolism Prevention (PEP) trial suggested an increased risk of cardiac ischemic outcomes with ASA therapy in patients undergoing surgery for a hip fracture. Although the PEP trial suggests that ASA therapy can prevent pulmonary emboli (hazard ratio 0.43, 95% CI 0.18–0.60), this result has failed to affect clinical practice, because only 25% of patients in the placebo group were receiving a low-molecular-weight heparin. The American College of Chest Physicians’ evidence-based guidelines recommend low-molecular-weight heparin, not ASA, for prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
ASA therapy in patients undergoing noncardiac surgery is associated with an increased risk of bleeding. In the PEP trial, there were 197 postoperative bleeding episodes requiring a transfusion among the 6679 patients randomly assigned to receive ASA, compared with 157 postoperative bleeding episodes requiring a transfusion among the 3808 control subjects ($p = 0.04$).\(^{25}\) Given the evidence that ASA prevents cardiovascular events in the nonperioperative setting,\(^{23}\) the conflicting RCT evidence surrounding the impact of ASA on perioperative cardiovascular events, and the likelihood of increased risk of bleeding associated with perioperative ASA therapy, determining the balance of benefits and risk of ASA prophylaxis in patients undergoing noncardiac surgery will require a large definitive RCT. Until then, physicians must weigh the increased risk of bleeding against yet unproven cardiovascular benefits.

### Acute and long-term management of major perioperative ischemic cardiac events

Unfortunately, there are no RCTs informing us how to manage perioperative ischemic cardiac events acutely or in the long term. Identifying and treating correctable causes (e.g., anemia and hypoxia) seems advisable. Although thrombolytic, antiplatelet and anticoagulant therapies are beneficial in the management of acute nonoperative MIs,\(^{25}\) these therapies in the acute perioperative setting are likely to have a different risk–benefit ratio. Drugs that are efficacious in the long-term management of nonoperative MI (e.g., ASA, ACE inhibitors, β-blockers and statins) may not have the same impact in the management of perioperative MI.\(^{26}\) Only RCTs specific to the perioperative period will leave us confident of generalizing results from other settings.

### Conclusions

Unrecognized MIs are common, and about half of all perioperative MIs may go unrecognized if physicians rely solely on clinical signs or symptoms. Perioperative troponin measurement and 12-lead ECGs can facilitate detection of clinically silent MIs as well as provide long-term prognostic information. Although several perioperative prophylactic interventions (α-,β-adrenergic agonist, β-blocker, statin, ASA and calcium-channel blocker therapies) may prevent major perioperative cardiac events, definitively establishing or refuting their benefit will require large, well-designed and conducted trials. Current evidence does not support a management strategy of preoperative coronary revascularization before noncardiac surgery.

### References

1. Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005;173(6):627-34.
2. Driscoll AH, Hobika JH, Eusten BE, Proger S. Clinically unrecognized myocardial infarction following surgery. N Engl J Med 1961;264:633-9.
3. Rosenman RH, Friedman M, Jenkins CD, Strauss R, Wurm M, Kositchek R. Clinically unrecognized myocardial infarction in the Western Collaborative Group Study. Am J Cardiol 1967;19:776-82.
4. Medalie JH, Goldbourt U. Unrecognized myocardial infarction: five-year incidence, mortality, and risk factors. Ann Intern Med 1976;84:526-31.
5. Grimm RH Jr, Tillinghast S, Daniels K, Neaton JD, Masiocchi S, Crow R, et al. Unrecognized myocardial infarction: experience in the Multiple Risk Factor Intervention Trial (MRFIT). Circulation 1987;75:II6-8.
6. Yano K, MacLean CJ. The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Intern Med 1989;149:1526-32.
7. Kannel WB, Cupples LA, Gagnon DR. Incidence, precursors and prognosis of unrecognized myocardial infarction. Adv Cardio 1990;37:202-14.
8. Sigurdsson E, Thorgergsson G, Sigvaldason H, Sigfusson N. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med 1995;122:96-102.
9. Jonsdottir LS, Sigfusson N, Sigvaldason H, Thorgergsson G. Incidence and prevalence of unrecognized and myocardial infarction in women. The Reykjavik Study. Eur Heart J 1996;17:1011-8.
10. Sheifer SE, Gersh BJ, Yanez ND III, Aide PA, Burke GL, Manolio TA. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol 2000;35:119-26.
11. Sheifer SE, Manolio TA, Gersh BJ. Unrecognized myocardial infarction. Ann Intern Med 2001;135:801-11.
12. Mangoano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tatoe IM. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med 1990;323:1781-8.
13. Ashton CM, Petersen NJ, Wray NP, Kiefe CI, Dunn JK, Wu L, et al. The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. Ann Intern Med 1993;118:904-10.
14. Badner NH, Knill RL, Brown JE, Nowick TV, Gelb AW. Myocardial infarction after noncardiac surgery. Am J Med 1998;105:372-8.
15. Fleischmann KE, Goldman L, Young B, Lee TH. Association between cardiac and noncardiac complications in patients undergoing noncardiac surgery: outcomes and effects on length of stay. Am J Med 2003;115:515-20.
16. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology / American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
17. Healey JH, Kagen LJ, Velis KP, Levine DB. Creatine kinase MB in skeletal mus-
chle and serum of spine-fusion patients. Clin Orthop Relat Res 1985;195:282-8.
18. Jules-Elysee K, Urban MK, De Boncote MC, Monacini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvas- tatin: a randomized trial. [discussion 975-6]. J Vasc Surg 2004;39:967-75.
19. Kertai MD, Boersma E, Klein J, Van Urk H, Bax JJ, Poldermans D. Long-
term prognostic value of asymptomatic cardiac troponin T elevations in pa-
tients after major vascular surgery. J Am Coll Cardiol 2003;41:1713-20.
20. Landesberg G, Mosseri M, Wolf YG, Bocher M, Basevitch A, Rudis E, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004;351:2795-804.
21. Mangano DT, Layug EL, Chou PT, Guyatt GH. Are the recommen-
dations to use perioperative beta-blocker therapy in patients undergoing noncar-
diac surgery based on reliable evidence? [editorial]. CMAJ 2004;171(3):245-7.
22. Mordasini P, Mikhailidis DP, Stansby G. Systematic review of antithromboly-
terapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:778-800.
23. Morris GE, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to pre-
duce perioperative cardiac ischemia. CMAJ Anesthesiol 1998;88:17.
24. Nissen SE, Shlipak MG, Kostis JB, Tuzcu EM, Schoenhagen P, Jansen J, et al. Coronary artery revascularization before elective major vascular surgery. N Engl J Med 2004;351(27):2795-804.
25. Oliveira MF, Goldman L, Julin DG, Holme I. Effect of niacin on periop-
erative cardiac complications during noncardiac surgery in patients with coronary heart disease: the European Mivazol Trial (EMIT). Anesthesiology 2000;93:674-81.
26. Panagiotakis K, Tsagarakis P, Goumas G, Antoniou G, Vlachos N, et al. Effect of niacin on perioperative cardiac complications during noncardiac surgery in patients with coronary heart disease: the European Mivazol Trial (EMIT). Anesthesiology 2000;93:674-81.
27. Perel P, Haskell WL, Chalmers TC, Collins R. Systematic review of antiplatelet ther-
apy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:778-800.
28. Philip BG, Barlow PN, Kurki TI, Vartiainen E, Timonen J, et al. Preop-
erative cardiac events and noncardiac surgery: the Statins for Risk Reduction in 675-9.
29. Quintero-Lopez N, Fernandez-Carreno CM, Lluch D, Sancho-Blazquez P, et al. Perioperative cardiac complications during non-cardiac surgery in patients with coronary artery disease. Eur Heart J 2009;30:1846-51.
30. Rockman SM, Urban MK, De Boncote MC, Monacini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvas-
tatin: a randomized trial. [discussion 975-6]. J Vasc Surg 2004;39:967-75.
31. Rose PG, Egger M, Davey Smith G, Black N, Henry D, Fletcher J, et al. Evidence for Noncardiac Surgery). Cardiology / American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol 2003;41:1713-20.
32. Stone JG, Foner P, Low LF, Johnson LL, Kambath BJ, Trinder L. Risk of myo-
icardial ischaemia during treatment and untreated hyperten-
sive patients. Br J Anaesth 1988;61:675-9.
33. Tait AM, Feagans C, Feagans J, Feagans B. Systematic review of antithromboly-
terapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:778-800.
34. Tilz RF, Stengel R, Drexler H, Zeymer U, Sabin C, et al. Prevention of peripera-
tive cardiac events and death events with low dose as-
perfusion Embolism Prevention (PEP) trial. Lancet 2003;355:1295-302.
35. Tousoulis D, Tousoulis G, Tousoulis N, Tousoulis E, Tousoulis I, Tousoulis J, et al. The effects of perioperative beta-blocker therapy in patients undergoing noncardiac surgery. Eur Heart J 2003;24:1110-6.
36. Urban MK, De Boncote MC, Monacini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvas-
tatin: a randomized trial. [discussion 975-6]. J Vasc Surg 2004;39:967-75.
37. Urban MK, De Boncote MC, Monacini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvas-
tatin: a randomized trial. [discussion 975-6]. J Vasc Surg 2004;39:967-75.
71. McDaniel MD, Pearce WH, Yao JS, Rossi EC, Fahey VA, Green D, et al. Sequential changes in coagulation and platelet function following femorotibial bypass. *J Vasc Surg* 1984;1:261-8.

72. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3 Suppl):338S-400S.

73. Collaborative overview of randomised trials of antplatelet therapy-III: Reduction in venous thrombosis and pulmonary embolism by antplatelet prophylaxis among surgical and medical patients. Antithrombot Trialists’ Collaboration. *BMJ* 1994;308:235-46.

74. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;324:71-86.

75. Danchin N, Urban P, De Benedetti F. Acute myocardial infarction. *Clin Epidemiol Biostat* 2004;12(10):188-230.

### Correspondence to:
Dr. P.J. Devereaux, Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, Rm. 2C8, McMaster University, 1200 Main St. W, Hamilton ON L8N 3Z5; fax 905 905 526-1333; philipj@mcmaster.ca

---

## Appendix 1: Recommended troponin threshold* for myocardial infarction based on concentrations corresponding to a coefficient of variation (CV) equal to 10%†

| Manufacturer; assay | Concentration corresponding to 10% CV imprecision, µg/L | Manufacturer; assay | Concentration corresponding to 10% CV imprecision, µg/L |
|---------------------|--------------------------------------------------------|---------------------|--------------------------------------------------------|
| Abbott Diagnostics  |                                                       | Dade Behring        |                                                       |
| AxSYM               | 1                                                     | Dimension Rxl, second generation | 1                                                     |
| Bayer Diagnostics   |                                                       | Opus, second generation    | 1                                                     |
| ACS:180             | 1                                                     | Stratus CS            | 1                                                     |
| Centaur             | 1                                                     | Diagnostic Products Corporation | 1                                                     |
| Immuno 1            | 1                                                     | Immulite One          | 1                                                     |
| Beckman Coulter     |                                                       | Ortho-Clinical Diagnostics | 1                                                     |
| Access, second generation | 0.06                                               | Vitros ECi            | 1                                                     |
| Access 2, second generation | 0.09                                               | Roche Diagnostics     | 1                                                     |
| BioMerieux          |                                                       | E 170                | T                                                     |
| Vidas               | 1                                                     | Elecsys 1010, third generation | T                                                     |
| Byk-Sangtec Diagnostica | 0.36                                              | Tosoh Corporation     | T                                                     |
| Liaison             | 1                                                     | AIA-21, second generation | 1                                                     |

*If troponin levels cannot be obtained, no creatine kinase MB isoenzyme (CK-MB) threshold is of equivalent diagnostic accuracy. A threshold that physicians may want to use, if troponin measurement is unavailable, is a CK-MB value at the 99th percentile of a reference control group.

†This appendix has been modified, with permission, from Table 3 in reference 21 (Panteghini M, Pagani F, Yeo KT, Apple FS, Christiansen RH, Dati F, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. *Clin Chem* 2004;50:127-32). © 2004 American Association for Clinical Chemistry.